AcelRx Pharmaceuticals Stock: Finally, Plan B (NASDAQ:ACRX)

Without knowledge of the DSUVIA deal it is hard to assess the prospect, so I retain a neutral rating with a tilt to buy. Read more about ACRX stock here.

Related Keywords

Germany ,Japan ,South Korea ,France ,Cincinnati ,Ohio ,United States ,French ,German ,Vadzim Kushniarou ,Ein Gesch ,B Das Konzept ,Nafamostat Niyad ,Vincent Angotti ,Niyad Nafamostat ,Clinical Development Of Niyad ,Department Of Anesthesiology ,Division Of Renal Diseases ,Nasdaq ,Ascs Ambulatory Surgical Centers ,George Washington University ,Acelrx Pharmaceuticals Inc ,Lowell Therapeutics Inc ,Us Army ,Department Of Medicine ,Acelrx Pharmaceuticals ,Key Opinion Leader ,Global Investment Conference ,Ambulatory Surgical Centers ,Commercial Sales ,Dod Sales ,Lowell Therapeutics ,Investigator Initiated ,Europe Licensor ,Niyad Deep ,Renal Replacement Therapy ,Emergency Use Authorisation ,Critical Care Medicine ,Renal Diseases ,Study Overview ,Nafamostat Study Overview ,Company Presentation ,Acute Care Nephrology ,Cincinnati Children ,Hospital Medical Center ,Chief Medical Officer ,Japanese Nafasmostat ,Breakthrough Device Designation ,Active Pharmaceutical Substance ,Commercialisation Timeline ,Niyad Commercialisation Timeline ,Pre Market Authorisation ,Intravascular Coagulation ,Respiratory Distress Syndrome ,